Physician profile
Ronald Litman
NPI 1578059630
$7,583.51
in general payments reported to CMS, 2019-2025
25 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.24 · 2021: $472 · 2022: $980 · 2023: $807 · 2024: $3,315 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,440 · Consulting Fee: $1,960 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,440.44 |
| Consulting Fee | $1,960.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,713.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $1,982.19 | 2024-2025 | |
| Senseonics, Incorporated | $1,713.86 | 2024 | Eversense |
| Abbvie INC. | $1,074.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $857.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $250.36 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $244.64 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $209.70 | 2021-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $190.74 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.41 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $164.98 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $108.45 | 2024-2025 | Fanapt |
| Amgen INC. | $104.47 | 2022-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $96.46 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $94.25 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $82.80 | 2022-2023 | Myrbetriq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.50 | 2021-2022 | |
| Exact Sciences Corporation | $36.86 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $36.27 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $27.06 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $19.74 | 2025 | Voquezna |
| Abbott Laboratories | $18.85 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $17.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.27 | 2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $14.24 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Litman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.